CADTH | Evidence Driven
CADTH | Evidence Driven

Sustained Release Oral Morphine, Injectable Hydromorphone, and Prescription Diacetylmorphine for Opioid Use Disorder: Clinical and Cost-Effectiveness, and Guidelines

Details

Files
Project Status:
Completed
Project Line:
Reference List
Project Sub Line:
Summary of Abstracts
Project Number:
RB1083-000

Question


  1. What is the comparative clinical effectiveness of sustained release oral morphine (SROM) versus standard of care (i.e., methadone or buprenorphine/naloxone) in opioid use disorder?

  2. What is the comparative clinical effectiveness of injectable hydromorphone or prescription diacetylmorphine versus standard of care (i.e., methadone or buprenorphine/naloxone) in opioid abuse disorder?

  3. What is the comparative clinical effectiveness of SROM versus injectable hydromorphone or prescription diacetylmorphine in opioid use disorder?

  4. What is the cost-effectiveness of SROM in opioid use disorder?

  5. What is the cost-effectiveness of injectable hydromorphone or prescription diacetylmorphine in opioid use disorder?

  6. What are the evidence-based guidelines regarding the use of SROM, injectable hydromorphone or prescription diacetylmorphine for opioid abuse treatment?


Key Message

Four systematic reviews, seven randomized controlled trials, two non-randomized studies and one economic evaluation were identified regarding sustained release oral morphine, injectable hydromorphone, or prescription diacetylmorphine for opioid use disorder. Additionally, one evidence-based guideline was identified regarding sustained release oral morphine, injectable hydromorphone, or prescription diacetylmorphine for opioid use disorder.


Files

Sustained Release Oral Morphine, Injectable Hydromorphone, and Prescription Diacetylmorphine for Opioid Use Disorder: Clinical and Cost-Effectiveness, and Guidelines Rapid Response April 13, 2017 View PDF

Related Content

Last Updated : April 13, 2017